GT Biopharma Inc Cash Flow Conversion Efficiency
GT Biopharma Inc cash flow conversion efficiency. Based on the latest financial reports, GT Biopharma Inc (GTBP) has a cash flow conversion efficiency ratio of -1.194x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.26 Million) by net assets ($3.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of GT Biopharma Inc (1985–2025)
Cash flow conversion efficiency of GT Biopharma Inc from 1985 to 2025. This chart illustrates how GT Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest GT Biopharma Inc stock price today for real-time trading data and today's change.
GT Biopharma Inc Cash Flow Conversion Ratio Explained
GT Biopharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
GT Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GT Biopharma Inc ranked by their cash flow conversion efficiency. Also see GT Biopharma Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Intensity Therapeutics, Inc. Common stock
NASDAQ:INTS
|
-0.183x |
|
WALLBOX N.V. CL.A EO-12
F:67E
|
N/A |
|
Eratex Djaja Tbk
JK:ERTX
|
0.189x |
|
Baselode Energy Corp
V:FIND
|
-0.665x |
|
Bhandari Hosiery Exports Limited
NSE:BHANDARI
|
0.015x |
|
Pioneer Lithium Ltd
AU:PLN
|
N/A |
|
Gyrodyne Company of America Inc
NASDAQ:GYRO
|
0.000x |
|
Ind-Swift Limited
NSE:INDSWFTLTD
|
-0.039x |
Annual Cash Flow Conversion Efficiency for GT Biopharma Inc (1985–2025)
The table below shows the annual cash flow conversion efficiency of GT Biopharma Inc from 1985 to 2025. Review GT Biopharma Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.79 Million | $-12.91 Million | -2.232x | -128.88% |
| 2024-12-31 | $-1.67 Million | $-12.90 Million | 7.727x | +752.58% |
| 2023-12-31 | $7.48 Million | $-8.85 Million | -1.184x | +8.70% |
| 2022-12-31 | $11.73 Million | $-15.22 Million | -1.297x | -82.07% |
| 2021-12-31 | $21.91 Million | $-15.61 Million | -0.712x | -388.69% |
| 2020-12-31 | $-29.43 Million | $-7.26 Million | 0.247x | +30.21% |
| 2019-12-31 | $-19.31 Million | $-3.66 Million | 0.189x | +120.18% |
| 2018-12-31 | $11.37 Million | $-10.68 Million | -0.939x | -4252.64% |
| 2017-12-31 | $251.69 Million | $-5.43 Million | -0.022x | -121.15% |
| 2016-12-31 | $-18.92 Million | $-1.93 Million | 0.102x | +10.74% |
| 2015-12-31 | $-50.57 Million | $-4.66 Million | 0.092x | +55.72% |
| 2014-12-31 | $-29.57 Million | $-1.75 Million | 0.059x | -15.25% |
| 2013-12-31 | $-6.33 Million | $-442.00K | 0.070x | -55.20% |
| 2012-12-31 | $-6.34 Million | $-987.00K | 0.156x | -17.49% |
| 2011-12-31 | $-5.10 Million | $-963.00K | 0.189x | -32.74% |
| 2010-12-31 | $-5.47 Million | $-1.53 Million | 0.281x | +71.46% |
| 2009-12-31 | $-5.72 Million | $-937.00K | 0.164x | +256.45% |
| 2008-12-31 | $-3.68 Million | $-169.00K | 0.046x | +127.71% |
| 2007-12-31 | $1.63 Million | $-270.00K | -0.166x | +95.18% |
| 2006-12-31 | $195.00K | $-671.00K | -3.441x | -481.67% |
| 2005-12-31 | $3.54 Million | $-2.09 Million | -0.592x | -229.06% |
| 2004-12-31 | $5.80 Million | $-1.04 Million | -0.180x | +31.70% |
| 2003-12-31 | $870.00K | $-229.00K | -0.263x | +68.19% |
| 2002-12-31 | $1.22 Million | $-1.01 Million | -0.828x | +69.05% |
| 2001-12-31 | $533.00K | $-1.43 Million | -2.674x | -180.15% |
| 2000-12-31 | $4.07 Million | $-3.89 Million | -0.954x | -3.60% |
| 1999-12-31 | $2.69 Million | $-2.48 Million | -0.921x | -27.55% |
| 1998-12-31 | $7.20 Million | $-5.20 Million | -0.722x | -2.31% |
| 1997-12-31 | $6.80 Million | $-4.80 Million | -0.706x | +26.13% |
| 1996-12-31 | $4.50 Million | $-4.30 Million | -0.956x | +22.47% |
| 1995-12-31 | $4.30 Million | $-5.30 Million | -1.233x | -2164.53% |
| 1994-12-31 | $6.70 Million | $400.00K | 0.060x | +110.45% |
| 1993-12-31 | $2.80 Million | $-1.60 Million | -0.571x | -391.43% |
| 1992-12-31 | $4.30 Million | $-500.00K | -0.116x | -167.44% |
| 1991-12-31 | $4.60 Million | $-200.00K | -0.043x | -123.19% |
| 1990-12-31 | $4.80 Million | $900.00K | 0.188x | +4.46% |
| 1989-12-31 | $3.90 Million | $700.00K | 0.179x | +474.36% |
| 1988-12-31 | $3.20 Million | $100.00K | 0.031x | +93.75% |
| 1987-12-31 | $3.10 Million | $50.00K | 0.016x | +111.29% |
| 1986-12-31 | $2.80 Million | $-400.00K | -0.143x | -47.62% |
| 1985-12-31 | $3.10 Million | $-300.00K | -0.097x | -- |
About GT Biopharma Inc
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, tha… Read more